GoldenGolden
Advanced Search
CureVac

CureVac

A biopharmaceutical company developing prophylactic and therapeutic application of messenger RNA, which can be used to develop vaccines. It was founded in 2000 and is located in Tübingen, Germany.

CureVac is a Germany-based biopharmaceutical company specializing in designing technology that utilizes messenger RNA (mRNA) as a data carrier which is capable of instructing the human body to create proteins to fight viruses, such as COVID-19. The company's technology has been used in multiple medical contexts such as cancer and rare diseases.

Product

The company has both an mRNA platform and production capabilities. Its platform analyzes millions of naturally occurring sequences and houses a nucleotide sequence library where data can be utilized by the CureVac team to created a customized mRNA therapy. The company works in partnerships with other biotechnology entities, such as Lilly, CEPI, and the Bill and Melinda Gates Foundation, to operate its pipeline taking therapeutics from a pre-clinical discovery phase through Phase 2 of clinical trials before finally producing the medical product.

CureVac also produces its mRNA therapies in its own facilities. The company has Good Manufacturing Practices (GMP) and its facilities are capable of producing standardized therapeutics. Industrial manufacturing of products is possible and could be used to produce a vaccine for COVID-19, pending clinical trials.

Timeline

June 30, 2021
CureVac announces appointment of Dr. Malte Greune as Chief Operating Officer and transition of Dr. Florian von der Mülbe to lead accelerated development of The RNA Printer(R)
February 2, 2021
CureVac raises a $450,000,000 venture round.
September 15, 2020
CureVac raises a $306,000,000 grant.
July 21, 2020
CureVac raises a $126,000,000 venture round from Qatar Investment Authority.
July 20, 2020
CureVac raises a $183,000,000 corporate funding round from GlaxoSmithKline.
June 15, 2020
CureVac raises a $458,800,000 venture round.
November 3, 2015
CureVac raises a $29,500,000 series F round from Baillie Gifford and Sigma Capital Group.
November 3, 2015
CureVac raises a $119,633,000 series F round from Baillie Gifford, Bill & Melinda Gates Foundation, Sigma Group and dievini Hopp Biotech Holding.
March 5, 2015
CureVac raises a $76,000,000 series E round from Bill & Melinda Gates Foundation.
September 18, 2012
CureVac raises a $104,432,000 series D round from dievini Hopp Biotech Holding.
Page 1 of 2

Funding rounds

People

Name
Role
LinkedIn

Baron Jean Stéphenne

Supervisory Board

Bernd Winterhalter

Interim Chief Development Officer

Christopher Karp

Scientific Advisory Board

Craig A. Tooman

Supervisory Board

Daniel Speiser

Scientific Advisory Board

Dirk Jäger

Scientific Advisory Board

Florian von der Mülbe

Chief Production Officer and Co-Founder

Franz-Werner Haas

Chief Operating Officer

Fred Zepp

Scientific Advisory Board

Friedrich von Bohlen und Halbach

Supervisory Board

George R. Siber

Scientific Advisory Board

Gerd Zettlmeissl

Scientific Advisory Board

Hans-Georg Rammensee

Scientific Advisory Board

Ingmar Hoerr

Founder, Chairman of the Executive Board and Chief Executive Officer

Jean-Paul Prieels

Scientific Advisory Board

Karim Fizazi

Scientific Advisory Board

Mariola Fotin-Mleczek

Chief Technology Officer

Mathias Hothum

Supervisory Board

Michael P. Manns

Scientific Advisory Board

Michel De Wilde

Scientific Advisory Board

Nina Bhardwaj

Scientific Advisory Board

Pierre Kemula

Chief Financial Officer

Ralf Clemens

Supervisory Board & Chairman of the Scientific Advisory Board

Stanley Plotkin

Scientific Advisory Board

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

CureVac Receives €80M from EU to Fund Coronavirus Vaccine Amid US Dispute

Jonathan Smith

Web

March 17, 2020

Germany's CureVac Says Low-Dose Coronavirus Vaccine Could Allow for Mass Production

Reuters

Web

March 13, 2020

Documentaries, videos and podcasts

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
October 12, 2021
FierceBiotech
With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year, and switching focus to its second mRNA asset with GlaxoSmithKline.
Ben Adams
August 16, 2021
FierceBiotech
Back in 2014, a German pharma and a then largely unknown fellow German biotech in CureVac penned a $600 million mRNA cancer pact. Buried in financials posted Monday morning, CureVac quietly reported that Boehringer Ingelheim has walked away from the deal, which was penned in 2014 and included $45 million upfront plus $556 million in biobucks.
Nick Paul
July 1, 2021
FierceBiotech
CureVac has highlighted the efficacy of its failed COVID-19 vaccine in adults aged up to 60 years as evidence the jab has a role to play in the response to the pandemic. The German biotech is pushing ahead with a regulatory submission in Europe despite achieving 48% efficacy in its phase 2b/3 trial.
BioSpace
June 30, 2021
BioSpace
CureVac N.V. today announced the appointment of Dr. Malte Greune as Chief Operating Officer (COO) effective July 1, 2021.
BioSpace
June 23, 2021
BioSpace
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that Dr. Ingmar Hoerr, former Founding-CEO and former member of the Supervisory Board of CureVac, has withdrawn his candidacy for nomination to the Supervisory Board.
June 23, 2021
AP NEWS
German biotech company CureVac said Wednesday that its founder has withdrawn his candidacy for the supervisory board for health reasons.Dr. Ingmar Hoerr, one of the leading scientists in the development of mRNA technology, was the company's founding chief executive and later chairman.
BioSpace Editorial Staff
June 22, 2021
BioSpace
Please check out the biopharma industry's COVID-19 stories that are trending for June 22, 2021.
Elie Dolgin, Nature magazine
June 22, 2021
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.
Reuters
June 18, 2021
@bsindia
The Delta variant is well on its way to becoming the dominant variant globally because of its increased transmissibility, says WHO chief scientist
Brandon May
June 17, 2021
BioSpace
The new findings likely throw a wrench in the company's plans to deliver millions of much-needed vaccine doses to the European Union soon.
The Hindu Net Desk
June 17, 2021
The Hindu
About 22.8% of adults in India, 43% of those aged above 45, and 46.6% of people aged above 60, have been administered at least one dose of a COVID-19 vaccine, until 8 p.m. on Wednesday
June 17, 2021
mint
The interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement.CureVac declined to say how many who got the shot got sick or how many received a placebo
Kyle LaHucik
June 16, 2021
FierceBiotech
German biopharmaceutical CureVac said its first-generation COVID-19 vaccine, CVnCoV, showed less than 50% efficacy against any severity of the disease.
Andrew Dunn
June 16, 2021
news.yahoo.com
CureVac's stock tanked after the announcement. The German biotech blamed variants in a press release.
BioSpace
June 2, 2021
BioSpace
CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid today announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer. The appointment of Dr. Edvardsen will take effect on August 1, 2021.
Carl Zimmer
May 28, 2021
www.nytimes.com
The German company is developing an RNA vaccine that could be substantially cheaper than Moderna or Pfizer.
Arlene Weintraub
May 17, 2021
FierceBiotech
Many biopharma companies are betting the novel coronavirus is here to stay--and they're continuing to develop vaccines and drug treatments to keep it under control. They include CureVac, which said the next-gen version of its mRNA COVID vaccine was effective in a rodent study, and Memo Therapeutics, which described the antibody drug candidate it's developing.
Joe Árvai, Dana and David Dornsife Professor of Psychology and Director of the Wrigley Institute for Environmental Studies, USC Dornsife College of Letters, Arts and Sciences, Lucca Henrion, Research Fellow at the Global CO2 Initiative, University of Michigan, Volker Sick, Arthur F. Thurnau Professor; DTE Energy Professor of Advanced Energy Research; and Director, Global CO2 Initiative, University of Michigan, and Lauren Lutzke, PhD student, USC Dornsife College of Letters, Arts and Sciences
May 14, 2021
news.yahoo.com
Consumer decisions could play a critical role in dealing with climate change. A study gauging perceptions was published May 13, 2021. FotographiaBasica via...
BioSpace
May 13, 2021
BioSpace
CureVac N.V. announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.
Carl Zimmer
May 5, 2021
www.nytimes.com
The German company CureVac hopes its RNA vaccine will rival those made by Moderna and Pfizer-BioNTech. It could be ready next month.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.